Relevance of a “Dear Doctor letter” to alert healthcare providers to new recommendations for vitamin D administration
- 20 May 2011
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 67 (7) , 681-686
Abstract
Purpose After reports of malaise in infants immediately after the oral administration of two brands of vitamin D solutions, a “Dear Doctor letter” (DDL) containing recommendations for the administration of vitamin D was sent to all French paediatricians and pharmacies and a large number of French general practitioners (GPs) with a predominantly paediatric practice. The DDL and a press release were published on the French Medicines Agency website and distributed via a mailing list. The objective of this study was to assess the effectiveness of such a DDL and to collect the opinions of healthcare professionals on the best way to provide them with information. Methods A questionnaire was sent to a national random sample of 145 paediatricians, 680 GPs and 230 pharmacists. Results Only 49% of responding paediatricians, 48% of GPs and 67% of pharmacists were aware of the warning. Among the participating healthcare professionals aware of the warning and who prescribed/dispensed these vitamins, 50% of paediatricians and 68% of GPs stated that they had changed their prescribing behaviour, and 68% of pharmacists stated that they had modified their advice when dispensing. According to the responding healthcare professionals, postal letters remained the best way to issue safety warnings. Some of the respondents suggested that the DDL be more distinctive in terms of being a DDL and that the information be more widely disseminated to other stakeholders involved in the healthcare system. Conclusions This survey of a national random sample of healthcare professionals revealed that many of the respondents paid little attention to the DDL and were therefore unlikely to change their practices. A potential supplementary method for disseminating recommendations for medicine administration could be to apply stickers on medicine boxes, as this approach has the additional advantage of directly informing the concerned population, i.e. the parents.Keywords
This publication has 24 references indexed in Scilit:
- Public Pharmacovigilance CommunicationDrug Safety, 2010
- A Decade of Safety-Related Regulatory Action in the NetherlandsDrug Safety, 2010
- Effectiveness of Safety Warnings in Atypical Antipsychotic DrugsDrug Safety, 2009
- Réactivité et communication des décisions de pharmacovigilance des autorités de santé vers les professionnels de santé : exemples du pergolide et du célécoxibTherapies, 2007
- The challenge of effectively communicating pateint safety informationExpert Opinion on Drug Safety, 2006
- Impact of regulatory labeling for troglitazone and rosiglitazone on hepatic enzyme monitoring compliance: findings from the state of Ohio medicaid programPharmacoepidemiology and Drug Safety, 2004
- Impact of mailed warning to prescribers on the co‐prescription of tramadol and antidepressantsPharmacoepidemiology and Drug Safety, 2004
- Impact of cisapride label changes on codispensing of contraindicated medicationsPharmacoepidemiology and Drug Safety, 2003
- Labelling and ???Dear Doctor??? LettersDrug Safety, 2002
- Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of ?dear doctor? lettersPharmacoepidemiology and Drug Safety, 2001